Actuate Therapeutics Inc

NASDAQ:ACTU

Biotechnology

Healthcare
$2.09 +2.96%

+$0.06 today

Market cap
$50.01M
Beta
0.53
P/E (TTM)
-2.3
EPS (TTM)
-$0.92
52W Low $1.58High $9.22

Volume 0.03M

Average 0.16M

ACTU Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Actuate Therapeutics IncNASDAQ: ACTU

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 23.54M shares rose 20.7% year over year, ahead of the +12.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +20.7% holds above the trailing-twelve-month pace of +12.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
23.54M+1.3% QoQ
Last fiscal yearDec 2025
21.02M+7.7% YoY
LTMMar 2026
21.96M+12.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.7%——
1 year+7.7%——
3-year CAGR+11.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
21.02M USD
Year-over-year change
+7.7%
3-year CAGR
+11.8%

Weighted Avg Shares vs competitors

How ACTU compares with its peers on the latest reported figures

  • ACTU's LTM Mar 2026 weighted avg shares of 21.96M shares is the 6th highest of the 9 companies compared; the peer median is 40.81M shares.
  • Its year-over-year change of +12.5% is the 4th highest of 9, against a peer median of +9.7%.
  • Over three fiscal years its annual growth of +11.8% compares with a peer median of +18.6%.
ACTU Competitors Peer median
Weighted Avg Shares for ACTU and competitors
Company Period LTM YoY 3-year CAGR
ALECAlector, Inc.LTM Mar 2026104.14M +6.5%+7.7%
NKTXNkarta, Inc.LTM Mar 202674.08M +0.6%+19.3%
SPROSpero Therapeutics, Inc.LTM Mar 202656.4M +3.7%+14.2%
PEPGPepGen Inc.LTM Mar 202644.2M +35.7%+39.2%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+4.7%
ACTUActuate Therapeutics IncLTM Mar 202621.96M +12.5%+11.8%
ELTXElicio Therapeutics, Inc.LTM Mar 202616.57M +32.5%+70.3%
MCRBSeres Therapeutics, Inc.LTM Mar 20268.99M +10.4%+17.9%
VORVor Biopharma Inc.LTM Mar 20265.81M +40.8%+70.9%
Peer median (excluding ACTU) 40.81M+9.7%+18.6%

Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development16.39M21.71M18.68M10.29M
Selling, General & Admin3.82M3.27M6.48M12.2M
Operating Expenses20.21M24.97M25.16M22.5M
Depreciation & Amortization63.61K272.85K2.14M0
EBITDA(20.08M)(24.43M)(25.16M)(22.21M)
EBITDA Margin————
Operating Income(20.21M)(24.97M)(25.16M)(22.5M)
Operating Margin————
Interest Income27.03K352.67K222.29K287.71K
Interest Expense16.2K43.64K(18.72K)20.25K
Other Income / Expenses47.41K229.21K(2.12M)267.46K
Income Before Tax(20.16M)(24.74M)(27.28M)(22.23M)
Pre-Tax Margin————
Income Tax Expense008000
Net Income(20.16M)(24.74M)(27.29M)(22.23M)
Net Margin————
EPS (Basic)(1.34)(1.65)(3.26)(1.06)
EPS (Diluted)(1.34)(1.65)(3.26)(1.06)
Weighted Avg Shares15.03M15.03M19.51M21.02M
Weighted Avg Shares (Diluted)15.03M15.03M19.51M21.02M

Actuate Therapeutics Inc

NASDAQ:ACTU

Intrinsic Alpha fair value

Locked

Current Price

$2.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.